Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Acasunlimab safety and pharmacokinetics in Japanese patients with advanced solid tumors
jRCT2031210112Completed
- Sponsor
- Genmab
- Start
- Jul 2021
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Open-label trial of acasunlimab in Nonhematologic neoplasms (2 arms), sponsored by Genmab. Primary endpoints: Number of participants with dose-limiting toxicities, Number of participants with adverse events and 5 more. Started Jul 2021; status: completed.
02
Drugs
acasunlimab
03
Conditions
Nonhematologic neoplasms
Beyond the preview
Go deeper on jRCT2031210112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031210112.